| Date | Time | Source | Headline | Symbol | Company |
| 04/25/2024 | 7:52AM | IH Market News | Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings | NASDAQ:SNY | Sanofi |
| 04/19/2024 | 7:31AM | IH Market News | Paramount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and More | NASDAQ:SNY | Sanofi |
| 02/23/2024 | 2:02PM | Edgar (US Regulatory) | Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). | NASDAQ:SNY | Sanofi |
| 02/23/2024 | 11:15AM | Edgar (US Regulatory) | Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | NASDAQ:SNY | Sanofi |
| 02/15/2024 | 12:09PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:SNY | Sanofi |
| 02/14/2024 | 3:57PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:SNY | Sanofi |
| 01/25/2024 | 2:29PM | GlobeNewswire Inc. | Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) | NASDAQ:SNY | Sanofi |
| 01/23/2024 | 7:23AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:SNY | Sanofi |
| 01/23/2024 | 6:05AM | Dow Jones News | Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update | NASDAQ:SNY | Sanofi |
| 01/23/2024 | 5:40AM | IH Market News | Wall Street Highlights: Vroom Shuts Down Online Car Sales, Ericsson Warns of Decline Outside China, and More | NASDAQ:SNY | Sanofi |
| 01/23/2024 | 1:00AM | PR Newswire (US) | Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B | NASDAQ:SNY | Sanofi |
| 01/17/2024 | 1:49PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:SNY | Sanofi |
| 01/09/2024 | 2:14AM | Dow Jones News | Sanofi Names Brian Foard Head of Specialty-Care Unit | NASDAQ:SNY | Sanofi |
| 12/27/2023 | 11:18AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:SNY | Sanofi |
| 12/21/2023 | 2:25AM | Dow Jones News | Sanofi Ends Drug Program After Late-Stage Trial in Lung Cancer Fails | NASDAQ:SNY | Sanofi |
| 12/19/2023 | 7:28AM | Dow Jones News | Innate Pharma Shares Rise after Sanofi Exercises Licensing Option | NASDAQ:SNY | Sanofi |
| 12/12/2023 | 5:50AM | IH Market News | Hasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic Antitrust Loss, and More | NASDAQ:SNY | Sanofi |
| 12/11/2023 | 5:18PM | Dow Jones News | Sanofi Terminates Agreement with Maze Therapeutics Following FTC Opposition | NASDAQ:SNY | Sanofi |
| 12/11/2023 | 1:50AM | Dow Jones News | Sanofi Sees Improvement in Trial Results of Cancer Drug Sarclisa | NASDAQ:SNY | Sanofi |
| 12/07/2023 | 2:34AM | Dow Jones News | Sanofi Myeloma Drug Sarclisa Met Primary Goal in Late-Stage Trial | NASDAQ:SNY | Sanofi |
| 12/07/2023 | 2:20AM | Dow Jones News | Sanofi Sees Annual Sales From New Pharma Assets Above $10.8 Billion by 2030 | NASDAQ:SNY | Sanofi |
| 12/06/2023 | 8:20AM | Dow Jones News | Trending: Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage Trials | NASDAQ:SNY | Sanofi |
| 12/06/2023 | 5:14AM | Dow Jones News | Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials | NASDAQ:SNY | Sanofi |
| 11/30/2023 | 9:23AM | Dow Jones News | Teva Closes Collaboration Deal With Sanofi on IBD Treatment | NASDAQ:SNY | Sanofi |
| 11/30/2023 | 8:30AM | Business Wire | Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment | NASDAQ:SNY | Sanofi |
| 11/27/2023 | 10:31AM | Dow Jones News | Trending: Sanofi's Notus Trial Meets Primary Endpoint | NASDAQ:SNY | Sanofi |
| 11/27/2023 | 2:40AM | Dow Jones News | Sanofi Says Notus Phase 3 Trial of Dupixent Met Primary Endpoint | NASDAQ:SNY | Sanofi |
| 11/27/2023 | 1:30AM | GlobeNewswire Inc. | Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease | NASDAQ:SNY | Sanofi |
| 11/07/2023 | 4:01PM | AllPennyStocks.com | Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time | NASDAQ:SNY | Sanofi |
| 11/07/2023 | 8:56AM | Dow Jones News | Sanofi Under Preliminary Probe in France Over Possible Market Manipulation, Source Says | NASDAQ:SNY | Sanofi |